23 Feb. 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced the first patient dose has been completed with next-generation EGFR Exon20ins inhibitor ABSK112 for non-small cells lung cancer (NSCLC).

​On 6 Feb. 2024, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”) announced that it had received the upfront payment of US$70 million upon the entry into a licensing agreement for pimicotinib（ABSK021）with Merck in December 2023, a leading science and technology company headquartered in Darmstadt, Germany. It marks the successful completion of the first step in this collaboration. The receipt of this upfront payment will further bolster Abbisko Therapeutics's cash reserves and facilitate its subsequent pipeline R&D and internationalization strategy.

On January 9, 2024, Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib（ABSK021） has been granted orphan drug designation（ODD） by the European Medicines Agency (EMA) for the treatment of inoperable tenosynovial giant cell tumor (TGCT). 

3 January 2024, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that ABSK051, a novel small molecule CD73 inhibitor, has completed the first patient dose. In November 2023, Abbisko Therapeutics obtained the clinical trial approval from the National Medical Products Administration (NMPA) of the People’s Republic of China. ABSK051 is about to enter the first-in-human (FIH) phase I clinical trial for the treatment of advanced solid tumors in China.

​14 December 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) today announced that its CSF-1R inhibitor pimicotinib（ABSK021）has been granted the fast track designation（FTD） by the U.S. FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients that are not amenable to surgery.

On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany.

8 November 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced the first patient has been dosed in the study titled “A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer ”at the leading site Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.

9 Nov 2023, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that ABSK051, a novel small molecule CD73 inhibitor, has obtained the clinical trial approval from the National Medical Products Administration (NMPA) of the People’s Republic of China. ABSK051 is about to enter the first-in-human (FIH) phase I clinical trial for the treatment of advanced solid tumors in China.

​8 Nov 2023, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that ABSK012, a highly selective small molecule inhibitor overcoming resistant mutations of fibroblast growth factor receptor 4 (FGFR4) in patients with advanced solid tumors, has obtained investigational new drug (IND) approval of the first-in-human (FIH) phase I clinical study from the U.S. FDA.

​3 November 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) announced that two important clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is taking place in Ireland from November 1 to 4, 2023. The two tenosynovial giant cell tumor （TGCT）clinical trial updates include reporting the design of the ongoing pivotal global multi-center phase III clinical trial and a further update of the phase Ib clinical trial of pimicotinib.